Abstract
p53 is a key tumor suppressor that plays a critical role in coordinating the response of cells to a diverse range of stress conditions, e.g. oncogenic activation, hypoxia or DNA damage. Induction of cell death by apoptosis in response to stress by p53 is crucial for the prevention of tumor development as well as for the response to anticancer therapy. p53 triggers apoptosis through multiple mechanisms, including mitochondrial and death receptor pathways, cytoskeleton changes, suppression of survival signalling, and induction of hypoxia. Lesions in the p53 pathway occur so frequently in cancer, regardless of patient age or tumor type, that they appear to be part of the life history of a majority of cancer cells. Given an extremely high potency of apoptosis induction by functional p53, it appears that anti-cancer strategies based on p53 reactivation should be efficient and applicable in a wide range of human tumors. Tumor cells are prone to p53-induced apoptosis due to oncogene activation. Therefore it is conceivable that p53-based therapeutic strategies will not require selective targeting of tumor cells.
Keywords: p53, apoptosis, mitochondrial, anti-cancer strategies, hypoxia
Current Cancer Drug Targets
Title: p53: Fighting Cancer
Volume: 4 Issue: 5
Author(s): Galina Selivanova
Affiliation:
Keywords: p53, apoptosis, mitochondrial, anti-cancer strategies, hypoxia
Abstract: p53 is a key tumor suppressor that plays a critical role in coordinating the response of cells to a diverse range of stress conditions, e.g. oncogenic activation, hypoxia or DNA damage. Induction of cell death by apoptosis in response to stress by p53 is crucial for the prevention of tumor development as well as for the response to anticancer therapy. p53 triggers apoptosis through multiple mechanisms, including mitochondrial and death receptor pathways, cytoskeleton changes, suppression of survival signalling, and induction of hypoxia. Lesions in the p53 pathway occur so frequently in cancer, regardless of patient age or tumor type, that they appear to be part of the life history of a majority of cancer cells. Given an extremely high potency of apoptosis induction by functional p53, it appears that anti-cancer strategies based on p53 reactivation should be efficient and applicable in a wide range of human tumors. Tumor cells are prone to p53-induced apoptosis due to oncogene activation. Therefore it is conceivable that p53-based therapeutic strategies will not require selective targeting of tumor cells.
Export Options
About this article
Cite this article as:
Selivanova Galina, p53: Fighting Cancer, Current Cancer Drug Targets 2004; 4 (5) . https://dx.doi.org/10.2174/1568009043332934
DOI https://dx.doi.org/10.2174/1568009043332934 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry Antimicrobial Activity of Willowherb (Epilobium angustifolium L.) Leaves and Flowers
Current Drug Targets Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy Insights into Cellular Uptake of Nanoparticles
Current Drug Delivery FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Anticancer Activity of Organogallium(III) Complexes in Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Surface Binding of Toxins and Heavy Metals by Probiotics
Mini-Reviews in Medicinal Chemistry Recent Progress in the Development of Selective TRPV1 Antagonists for Pain
Current Topics in Medicinal Chemistry The Vitamin D/CYP24A1 Story in Cancer
Anti-Cancer Agents in Medicinal Chemistry Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews Free Radical Attack on Cholesterol: Oxysterols as Markers of Oxidative Stress and as Bioactive Molecules
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Nanomaterials in the Pharmaceuticals: Occurrence, Behaviour and Applications
Current Pharmaceutical Design